hES-T-MSC Differentiation via Trophoblast Intermediate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human embryonic stem cells (hESCs) into mesenchymal-like stem cells (MSCs) are inefficient, producing low yields of low purity cells with limited immunosuppressive effects, and pose safety concerns due to the use of animal feeder cells and variable donor tissue quality.
Innovation Solution
A method involving the intermediate differentiation of hESCs into trophoblasts to produce hES-T-MSCs, which are then differentiated into high-purity, high-yield MSCs with enhanced immunosuppressive properties, using a serum-free medium with BMP4 and TGFβ inhibitors, and culturing on specific coatings to express adult MSC markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods are used to differentiate hESCs into MSCs, then the process is simpler, but the yield and purity of MSCs are low
Solution Approach 1:
The differentiation process is divided into distinct sequential stages: hESC culture, trophoblast induction, and MSC differentiation. Each stage uses specific culture conditions and markers to ensure high purity at each transition point, ultimately achieving high-yield, high-purity MSC production.
Solution Approach 2:
The method performs preliminary trophoblast induction before MSC differentiation. By first generating trophoblasts from hESCs under defined conditions and then differentiating them into MSCs, the process ensures high purity at each stage and eliminates the need for complex selection methods.
2Reliability
If adult tissue-derived MSCs are used, then the source is limited and quality varies, but the method is currently available
Solution Approach 1:
The method extracts MSCs from hESCs through a defined differentiation pathway via trophoblasts, eliminating dependence on adult tissue donors. This provides an unlimited, consistent, and safe source of high-quality MSCs suitable for clinical applications.
Solution Approach 2:
The method changes the source parameter from adult tissues to hESCs and controls differentiation through specific culture parameters (serum-free medium, BMP4, TGFβ inhibitors). This ensures consistent quality and eliminates variability associated with donor age, health status, and tissue type.
3Quantity of substance
If adult-derived MSCs are expanded in vitro, then enough cell numbers are obtained, but immunosuppressive and homing abilities decrease
Solution Approach 1:
The method performs preliminary differentiation of hESCs into MSCs under optimized conditions before expansion. This ensures that the MSCs maintain their immunosuppressive and homing abilities even after extensive in vitro expansion, making them suitable for clinical use.
4Reliability
If animal feeder cells are used in hESC culture, then the culture is maintained, but safety concerns arise
Solution Approach 1:
The method removes animal feeder cells from the culture system and replaces them with defined serum-free medium containing BMP4 and TGFβ inhibitors. This eliminates safety concerns related to animal pathogens while maintaining efficient hESC culture and differentiation.
Solution Approach 2:
The method uses disposable, defined chemical factors (BMP4, TGFβ inhibitors) instead of living animal feeder cells. These factors can be added to the culture medium and removed, providing a safe, controllable, and scalable system for MSC production.
Data Source
AI summary
The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblast in hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically. T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.